| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | HGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6464H9932N1708O2010S46 |
| Molar mass | 145207.27 g·mol−1 |
  (what is this?) (verify) | |
Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors.[1]
Rilotumumab was in development by Amgen, Inc. until in November 2014, when Amgen announced it had halted all clinical trials of the compound in advanced gastric cancer (including two Phase III studies) after one of the trials found an increase in the number of deaths in those who were taking rilotumumab and chemotherapy when compared to those who were only administered chemotherapy.[2][3]
YouTube Encyclopedic
-
1/3Views:347475665
-
PD-L1 as a Biomarker in Squamous Non-Small Cell Lung Cancer
-
Molecular Profiling - interview with Sandeep "Bobby" Reddy, MD, at ASCO 2012
-
Expert Video Viewpoints on Castration-Resistant Prostate Cancer - Section 4
Transcription
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab" (PDF). American Medical Association.
- ^ "Amgen scraps trials of drug for advanced stomach cancer". yahoo.com. 24 Nov 2014. Retrieved 24 Nov 2014.
- ^ "Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer". 24 November 2014.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 19 May 2023, at 15:28